Alligator Bioscience to Host Conference Call to Provide Full Year Report 2017 Business Update
Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 16 February 2018, at 08:00 am CET, Alligator Bioscience will publish its report fo ...
Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study
Lund, Sweden, 25 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...
Alligator Bioscience appoints new VP Business Development
Lund, Sweden, 18 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...
Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference
Lund, Sweden, 4 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunother ...
Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Alligator Bioscience expands management team
Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...
Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017
Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...
Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB
Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...
Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...